

Attorney Docket No.: 4394.214-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

Express Mail Label No. EL293690221US
Date of Deposit June 3, 1999

Sir:

This is a request for filing a **continuation** application under 37 C.F.R. 1.53(b)
of

Applicant(s): Svendsen et al.

Title: α -Amylase Mutants

137 pages of specification 13 sheets of formal drawings 21 pages of Sequence
Listing

2 sheets of Declaration and Power of Attorney

[x] The filing fee is calculated as follows:

Basic Fee:	\$760.00
Total Claims: 2 - 20 = 0 x 18 =	\$0
Independent Claims: 2 - 3 = 0 x 78 =	\$0
Total Fee:	\$760.00

Priority of Danish application serial nos. 1256/95 and 1192/95, filed November 10, 1995 and October 23, 1995, respectively, is claimed under 35 U.S.C. 119. Certified copies thereof were submitted with USSN 08/600,908. A certified copy of 0128/95 filed February 3, 1995 is submitted herewith.

The benefit of application serial no. 08/600,908 filed on February 13, 1996 in the U.S. and PCT/DK96/00057 filed February 5, 1996 in the PCT is claimed under 35 U.S.C. 120.

Address all future communications to Steve T. Zelson, Esq., Novo Nordisk of North America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY 10174-6401.



Annex

Reza Green, Reg. No. 38,475
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

[illegible]

A

Attorney Docket No.: 4394.214-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EXPRESS MAIL CERTIFICATE

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

Re: U.S. Patent Application for
"α-Amylase Mutants"
Applicants: Svendsen et al.

Sir:

Express Mail Label No. EL293690221US

Date of Deposit June 3, 1999

I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
2. Patent Application
3. Copy of executed Combined Declaration and Power of Attorney
4. Preliminary Amendment
5. Certified Copy of Priority Application (0128/95)
6. 13 Sheets of formal Drawings
7. Information Disclosure Statement
8. Form PTO-1449
9. Request Transfer of Computer Readable Sequence Listing From Parent Case
10. Sequence Listing

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231.

Gina Maldonado

(Name of person mailing paper(s) or fee)

Gina Maldonado

(Signature of person mailing paper(s) or fee)

Mailing Address:
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10017
(212) 867-0123